LUNG-ROLL: Treatment patterns and cost of illness of lung cancer in Canada: exploring the feasibility of generating rolling data leveraging provincial cancer registries

Summary

Client: IQVIA Solutions Canada Inc.

Project ID: P2023-183/ 2026 0980 007 000

Research Question/Objectives: Lung cancer is the most common type of cancer and the leading cause of cancer-related deaths in Canada. It is primarily categorized into two main types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for over 80% of lung cancer cases and has a low overall 5-year survival rate. SCLC comprises approximately 15% of lung cancers and is also associated with poor survival outcomes post-diagnosis.

The therapeutic landscape for both NSCLC and SCLC has transformed in recent years, with clinical trials demonstrating promising results for immune checkpoint inhibitors (ICIs) and other novel therapies. Given the limited data available on the patient journey and treatment mapping for lung cancer in Canada, it is crucial to leverage existing health administrative databases to provide context and understanding of the current and evolving therapeutic landscape.

The aim of the LUNG-ROLL study is to continuously extract the most recent administrative data to better understand the epidemiological incidence, treatment patterns, and healthcare resource utilization (HCRU) for lung cancer in Canada.

Objectives:
Primary Objectives

1. To describe treatment patterns (see Table 9) for patients with lung cancer from January 2018 to the end of the analysis period, based on the latest available data.

Secondary Objectives

1. To estimate the incidence and prevalence of lung cancer, by calendar year, from January 2018 to the end of the analysis period, based on the latest available data.
2. To characterize the baseline patient demographic and clinical characteristics (see Table 10) of patients with lung cancer from January 2018 to the end of the analysis period, based on the latest available data.
3. To assess relevant time to event endpoints (overall survival, duration of treatment by line of therapy [LoT], time from diagnosis to 1st line treatment initiation, time from 1st line discontinuation to 2nd line initiation, time to subsequent treatment or death) and treatment attrition rates for patients with lung cancer from January 2018 to the end of the analysis period, based on the latest available data.
4. To estimate the HCRU and associated costs for patients with lung cancer from January 2018 to the end of the study analysis period, based on the latest available data.

Exploratory Objectives

1. To assess the objectives above by stratification factors such as sub-provincial geographic regions (i.e., Local Health Integration Networks [LHINs] in Ontario), cancer type (NSCLC and SCLC), histology, stage, treatment class, and year of diagnosis.

Status: In progress